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Abstract
Background: The exact etiology of ischemic stroke remains unclear, because multiple genetic
predispositions and environmental risk factors may be involved, and their interactions dictate the
complexity. Family-based studies provide unique features in design, while they are currently
underrepresented for studies of ischemic stroke in developing countries. The Fangshan/Family-
based Ischemic Stroke Study In China (FISSIC) program aims to conduct a genetic pedigree study
of ischemic stroke in rural communities of China.
Methods/Design: The pedigrees of ischemic stroke with clear documentation are recruited by
using the proband-initiated contact method, based on the stroke registry in hospital and
communities. Blood samples and detailed information of pedigrees are collected through the health
care network in the rural area, and prospective follow-up of the pedigrees cohort is scheduled.
Complementary strategies of both family-based design and matched case-spousal control design
are used, and comprehensive statistical methods will be implemented to ascertain potential
complex genetic and environmental factors and their interactions as well.
Discussion: This study is complementary to other genetic pedigree studies of ischemic stroke,
such as the Siblings With Ischemic Stroke Study (SWISS), which are established in developed
countries. We describe the protocol of this family-based genetic epidemiological study that may be
used as a new practical guideline and research paradigm in developing countries and facilitate
initiatives of stroke study for international collaborations.
Background
Stroke is a major cause of disability and mortality for
adults worldwide [1]. Epidemiological studies have sug-
gested an increase in the incidence of stroke over past dec-
ades in China [2] and other developing countries [3],
whilst the proportion of ischemic stroke in China is
increasing [4]. Both family history and twin studies pro-
vide evidence for a strong genetic component of ischemic
stroke [5,6], but the molecular basis for genetic back-
ground of common ischemic stroke remains unclear [7,8].
The ability to identify high-risk genetic factors could pro-
mote advances both in the discovery of novel pharmaceu-
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for public health.
Genetic linkage analysis is a powerful tool for identifying
genetic predispositions for instance, the deCODE genetics
group in Iceland has identified the novel STRK1 locus on
chromosome 5q12 by studying 476 Icelandic patients
with stroke within 179 extended pedigrees [9]. Another
example is the Siblings With Ischemic Stroke Study
(SWISS), which is an ongoing multi-centered genetic
study in North America [10,11]. Genetic association anal-
ysis remains a useful and more popular tool for fine map-
ping of complex disease genes in regions of linkage.
Numerous association studies using a candidate gene
approach have been attempted for ischemic stroke, while
the results are conflicting and far from conclusive [12].
This inconsistency is often ascribed to small samples with
inadequate statistical power, phenotype definition, bio-
logical complexity, inter-population heterogeneity, envi-
ronmental exposures, analytical method and population
stratification. The effect of population stratification on the
results of association analyses are potentially even more
severe especially when small effects are studied in very
large studies [13]. However, family-based design provides
a useful complementary strategy because of its robustness
to population admixture and stratification [14,15]. But as
an elderly-onset disease, rare family-based genetic studies
are available for ischemic stroke so far.
Several additional factors affect the study quality, with
appropriate sample recruitment strategy, logical variant
selection, minimum genotyping error, relevant data anal-
ysis, and valid interpretation all essential to generation of
robust findings [16]. Consequently, questions of study
design, implementation, statistical methods, and interpre-
tation can be important. Herein we describe the protocol
of a family-based genetic study for ischemic stroke in Chi-
nese population, the Fangshan/Family-based Ischemic
Stroke Study In China (FISSIC).
Methods/Design
Overview and objectives
The FISSIC program is a community-based and hospital-
centered genetic epidemiological study of ischemic stroke.
The study design has two components: first, a family-
based study of ischemic stroke pedigrees, including
probands, their siblings, and their parents; second, the tra-
ditional matched case-control study of ischemic stroke
cases and their unaffected spouses. Cases with confirmed
ischemic stroke are included as probands; after their
informed consent is obtained, their parents, siblings, and
unaffected spouses are recruited and screened by using the
proband-initiated contact method [10]. Stroke status is
verified at the central hospital (the First Hospital of Fang-
shan District, Beijing, China), and the index stroke for
each case is subtyped by medical records. Baseline clinical
and demographic data are collected by questionnaire, and
longitudinal follow-up visits are scheduled. Blood sam-
ples are collected from all enrolled participants through
the three-tier prevention and health care network (village,
township and county level) in the study area. The samples
are sent to the central laboratory for processing, testing,
and genotyping. The genotype data are then merged with
the clinical, environmental, and follow-up data for analy-
sis. Comprehensive statistical methods are applied to
both family-based and case-control data to ascertain
potential complex genetic and environmental factors and
their interactions.
The primary aim of the FISSIC is to study which genetic
factors predispose to ischemic stroke, and the exploratory
objectives are threefold:
1. To study predisposition of putative risk factor polymor-
phisms and their haplotypes in cases with different sub-
types of ischemic stroke.
2. To investigate whether any association found between
ischemic stroke and the panel of tested polymorphisms is
influenced by sex, age, or smoking status and other envi-
ronmental risk factors due to gene-environment interac-
tions.
3. To detect and characterize the potential epistasis or
gene-gene interactions between putative risk factor poly-
morphisms.
Understanding these objectives would be facilitated by
having the following information collected in the FISSIC
program: (1) DNA to document genetic predispositions,
(2) environmental risk factor data obtained from the
structured questionnaire, (3) serum indicators testing as
intermediate phenotypes, and (4) regular follow-up clini-
cal evaluations to document the occurrence of incident
ischemic stroke.
Study area selection
The Fangshan District (39°30'~39°55' N,
115°25'~116°15' E), with an area of 1,866.7 square kil-
ometers and a population of 760,000, is situated 45 kil-
ometers southwest of downtown Beijing in China (Figure
1). The region, which is 60% mountainous, was selected
because its population is representative of the rural north-
ern Han Chinese. Furthermore, similar to the "stroke belt"
in the south-eastern United States, this area is located in
the "stroke belt" of China [17]. The First Hospital of Fang-
shan District is the central hospital in the study, and pro-
vides stroke unit for both primary and tertiary care to the
rural population. Thus, sufficient cases have been pro-
posed to enroll for the study.Page 2 of 9
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Four groups of subjects will be studied: ischemic stroke
probands, their siblings, their parents, and unaffected
spouses.
Probands will include all patients aged above 18 years,
who are newly or have been ever referred to the First Hos-
pital of Fangshan District with computerized tomography
(CT) or magnetic resonance imaging (MRI) confirmed
ischemic stroke. Stroke is defined according to the World
Health Organization (WHO) criteria as commonly used
[17]. Probands will not be excluded from the study for
radiographic evidence of hemorrhagic transformation of
an ischemic stroke. If probands have had more than one
ischemic stroke, the most recent is the proband index
stroke. Detailed inclusion and exclusion criteria for
enrollment and recruitment are given in Table 1.
Siblings are eligible for inclusion if they have a full sibling
participating in the study as a proband, have also aged
above 18 years at the time of enrollment, have provided
written informed consent, and agreed to donate blood
samples. Step siblings and adopted siblings are not eligi-
ble. Parents of the probands will be recruited whenever
possible, but step parents are ineligible. All stroke-free
spouses of probands are eligible to serve as additional
controls.
Recruitment procedures
The FISSIC program procedure is summarized in Figure 2.
Ischemic stroke probands will be enrolled in two parts:
incident cases from the central hospital and prevalent
cases from communities.
In part I, all patients with suspected stroke admitted to the
neurology services at the central hospital are screened in
the hospital-based stroke registry. A study neurologist will
invite qualified patients to participate in a nontherapeutic
stroke genetics study as probands, and then probands or
their surrogates will take invitation letters to family mem-
bers living nearby. The family members, who are inter-
ested in the study and willing to join, may call the Contact
Center for details or register.
In part II, patients with a history of CT- or MRI-confirmed
ischemic stroke, will be registered through the commu-
nity-based health care networks in this rural area. With
their permission, probands' medical records will be
checked for qualification, and only after their family
members also register in the study, will the next stage start.
The Contact Center will not contact family members
directly before they register.
All probands and their family members will be identified
and arranged to any of the nearest community sites in the
health care network or the Central Hospital with their
own unique ID numbers. At the promised time and site
convenient to the subjects, they will be evaluated by a
study investigator according to a standard questionnaire
and take the physical examination with informed consent,
and then blood samples are collected by professional
nurses. All the subjects will be informed about the study
and agree for blood sampling and medical records review-
ing by the study, thereafter written informed consent will
be obtained.
Data collection
All participants are interviewed in person by the study
investigators, and will complete the following informa-
tion:
Questionnaire
The structured questionnaire collects information on
demographic characteristics (age, sex, education, etc),
family history (stroke history of family members), medi-
cal history (age of first onset, diagnosis and treatment of
stroke and other chronic diseases), environmental and
lifestyle risk factors (smoking, drinking, physical activity,
etc) and for women, history of menstruation and preg-
nancy.
Geographic map of the Fangshan/Family-based Ischemic Str ke Study In China ( ISSIC) program regionFigure 1
Geographic map of the Fangshan/Family-based 
Ischemic Stroke Study In China (FISSIC) program 
region. The cross symbol and spots symbols in the map of 
Fangshan indicate the Central Hospital (the First Hospital of 
Fangshan District) and Community Register Sites respec-
tively.Page 3 of 9
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questionnaire by all participants in FISSIC program,
detailed medical records will be checked retrospectively
for positive reporting of stroke history to verify the diag-
nosis, and then will be labeled as "Cases"; the Question-
naire for Verifying Stroke-Free Status (QVSFS) [18,19] will
be used for negative reporting of stroke history to avoid
the bias of misclassification, negative answers for all items
contained in the QVSFS will be labeled as "Controls";
Otherwise, the one with positive reporting but without
medical records and the one with negative reporting while
fail in screening of the QVSFS will be labeled as "Uncer-
tainties", which are expected to be evaluated in the follow-
up scheme.
Clinical evaluations
For each case of ischemic stroke, a study neurologist will
check the medical records for evaluation, including
patient history, physical examination, CT or MRI of the
head, and laboratory testing. Where clinically indicated,
the evaluation may also include magnetic resonance ang-
iography, carotid ultrasonography, transcranial cerebral
Doppler ultrasonography, color duplex flow imaging,
resting and ambulatory electrocardiography, intracranial
arterial imaging, and additional serum testing. Two differ-
ent neurologists will subtype according to the Trial of Org
10172 in Acute Stroke Treatment (TOAST) criteria [20],
and when the two neurologists disagree, the final decision
will be made by the Stroke Verification Committee (SVC).
This is a central specialist committee independent of the
study neurologists, which adjudicates the diagnosis and
subtype of ischemic stroke.
Physical examination
During the physical examination, anthropometric meas-
urements will be obtained by trained and certified observ-
ers. Height will be measured without shoes by a fixed
stadiometer and weight without heavy clothing by tradi-
tional scales. Body mass index is calculated as weight to
height squared (kg/m2). Waist and hip circumferences are
measured with patients standing relaxed and in light
clothing. Waist circumference is measured horizontally at
the midpoint between the lower costal margin and the
iliac crest, and hip circumference at the level of maximum
extension of the buttocks. Blood pressure will be meas-
ured three times at the right brachial artery by using a
sphygmomanometer after the participant has been resting
a seated position for 5 minutes.
Biochemical measures
Overnight fasting venous blood samples will be obtained
to measure lipids, glucose, and other serum indicators.
Blood specimens will be processed at the examination
center and shipped to a central clinical laboratory in the
Central Hospital for laboratory assays. Serum glucose,
blood urea nitrogen, creatinine, concentrations of total
cholesterol, triglycerides, low-density lipoprotein choles-
terol, and high-density lipoprotein cholesterol will be
measured by using the Hitachi 7180 autoanalyser
(Hitachi High-Technologies Corp., Tokyo, Japan). Using
the same autoanalyzer, serum apolipoprotein A-I, apoli-
poprotein B, apolipoprotein E, Lipoprotein (a) and high-
sensitivity C-reactive protein will be determined by an
immunoturbidimetric assay. Serum total homocysteine,
folic acid, and vitamin B12 will be measured by immu-
noassay with the IMX Analyzer (Abbott Laboratories,
USA). Additional blood samples will be frozen for future
reference. Sera will be stored at -80°C, and blood clots
will be stored at -20°C until DNA extraction.
Follow-up
The follow-up scheme will be developed for longitudinal
assessments based on age and initial physical examina-
tions. For example, subjects labeled as the "Uncertainties"
or siblings with high blood pressure will be followed up
most frequently. However, younger siblings will be fol-
Flow chart for recruitment of ischemic stroke probands and their rel tive cont ols in FISSIC programigur  2
Flow chart for recruitment of ischemic stroke 
probands and their relative controls in FISSIC pro-
gram. Abbreviations: FISSIC, the Fangshan/Family-based 
Ischemic Stroke Study In China; IS, ischemic stroke; QVSFS, 
the Questionnaire for Verifying Stroke-Free Status.Page 4 of 9
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resources. The link between the baseline and the follow-
up will be made by means of a unique ID number
assigned to each participant. The purposes of follow-up
are (1) to evaluate some subclinical stroke longitudinally
and avoid the bias of misclassification, (2) to improve the
recruitment of family members, and (3) to provide health
education and promote healthy behavior.
Selection of candidate genes and genotyping
Exhaustive genotyping for association in the human
genome is impractical. Candidate genes for ischemic
stroke are grouped into those for lipid metabolism, renin-
angiotensin system, nitric oxide production, homo-
cysteine metabolism, hemostasis, and other pathways [7].
Candidate genes in the first stage of the FISSIC program
include genes for apolipoprotein E (ApoE), lipoprotein
lipase (LPL), angiotensin-1-converting enzyme (ACE),
endothelial nitric oxide synthase (eNOS), 5, 10-methyl-
enetetrahydrofolate reductase (MTHFR), and plasmino-
gen activator inhibitor 1 (PAI-1). These genes were
selected because the gene product might relate to patho-
genesis of disease. For example, hyperhomocysteinemia,
atherosclerosis, and thromboembolism have been impli-
cated in the development of ischemic stroke; however,
hitherto results on associations between polymorphisms
in these common genes and risk of ischemic stroke are
conflicting [12]. Moreover, data in the Chinese popula-
tion from the International HapMap Project [21] will
facilitate the selection of tag-SNPs in these genes for hap-
lotype analysis.
DNA from all subjects will be isolated from blood clots by
phenol/chloroform extraction and ethanol precipitation,
according to the standard procedure. Genotyping will be
performed using the TaqMan fluorogenic 5' nuclease
assay (Applied Biosystems). All PCR and end point fluo-
rescent readings will be undertaken on an ABI PRISM
7900 HT sequence detection system (Applied Biosys-
tems). Genotyping will be performed for the polymor-
phisms of interest, including ApoE ε4, MTHFR C677T,
eNOS G894T, PAI-1 4G/5G, ACE I/D, and LPL S447X pol-
ymorphisms. In addition, several other polymorphisms
may also be studied. The genotyper will be blinded to out-
come and stroke subtype.
Sample size and recruitment goals
We anticipate that the study sample will be mainly native
Han Chinese from rural areas of northern China, and the
baseline risk for ischemic stroke in this study population
(P0) is 0.005; giving type I error (α = 0.05) and type II
error (β = 0.20) for two-sided test, the sample size require-
ments for case-sibling, case-parent and matched case-con-
trol design of gene-gene interaction are dependent on the
frequency of the polymorphisms of candidate genes, all
designs provide an estimate of interaction on a multipli-
cative scale. The common polymorphisms of candidate
genes we selected above have considerable allele fre-
quency, for example, considering the allele frequency of
0.344 and 0.236 for MTHFR 677C and eNOS 894T respec-
tively in this population from prior study, set 2.0 for the
main gene effect (RG, RH), 3.0 for gene interaction effect
(RGH) and dominant for mode of inheritance, the sample
size requirements calculated by the QUANTO [22] pro-
gram (Version 1.2.1) are 557 for case-sibling design, 321
for case-parent design and 418 for matched case-control
design respectively.
Because ischemic stroke is a late-onset disease, and
recruiting sufficient case-parents trios will be almost
impossible, case-sibling pairs will be considered when cal-
culating recruitment goals. Each inhabitants over 60 years
old has average 3.5 siblings in this area in 2003, suppose
every proband with two siblings consist 2 case-sibling
pairs, nearly 280 pedigrees is needed. Considering miss-
ing data, genotyping error and stoke subtyping, sample
Table 1: Inclusion and exclusion criteria for probands in the FISSIC program
a Inclusion criteria
1. Diagnosis of at least one ischemic stroke confirmed by the study neurologist on the basis of history, medical records, and head imaging by CT or 
MRI;
2. At least 18 years old by the time of enrolment in the study;
3. At least one full sibling or parent alive in areas nearby;
4. Written informed consent by the patient or surrogate.
b Exclusion criteria
1. Diagnosis of TIA only;
2. Diagnosis of vasospasm after subarachnoid hemorrhage;
3. Diagnosis of some Mendelian disorders: CADASIL, Fabry disease, MELAS, or sickle cell anaemia;
4. Diagnosis of iatrogenic ischemic stroke associated with a surgical/interventional procedure such as coronary artery bypass grafting, carotid 
endarterectomy, or heart valve surgery;
5. Diagnosis of ischemic stroke associated with autoimmune condition or endocarditis.Page 5 of 9
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grees. Recruitment began in June 2005 and is expected to
continue until December 2010.
Statistical methods
Because different types of designs are involved in the FIS-
SIC program, including family-based design and case-
control design, comprehensive statistical methods are
under consideration. In general, for the family-based
design with probands, siblings and parents, the Family
Based Association Test (FBAT) method [23] will be used
for association analysis. In addition, the Association in
the Presence of Linkage (APL) test [24] is another family-
based association method for nuclear families with multi-
ple affected siblings and missing parental genotypes. For
cases with affected siblings, linkage analysis will be per-
formed by the affected sib pair (ASP) method, and dis-
cordant sib pairs (DSPs) will enhance the ASP linkage
analysis to detect epistasis. For example, the Haseman-
Elston (HE) regression method [25] may be used for the
linkage analysis of quantitative traits. DSPs can also be
compared as a matched case-control design with homog-
enous genetic background, while unaffected spouses can
be compared as the matched case-control design with
unrelated genetic background. Some conventional and
novel approaches will be implemented in the case-control
design for detecting associations and interactions for
example, the logistic regression and the multifactor
dimensionality reduction (MDR) method [26].
Ethical aspects
This study was approved by the ethics committee of
Peking University Health Sciences Center and each local
institutional review board. Oral informed consent will be
obtained from every participant before data collection,
and written informed consent will be signed by every
study participant or surrogate before blood sample collec-
tion. All participants will receive feedback reports and sug-
gestions about their own health status under the privacy
policy, and participants with untreated conditions identi-
fied during the examination will also be referred to a pri-
mary healthcare provider.
Because of the highly sensitive nature of genetic informa-
tion, no individual information on genetic data will be
informed. Each investigator who obtains or has access to
individual personal identifiers is blinded to genotypic
data. As commonly addressed in genetic studies [27], the
following rules will be obeyed: Subjects may consent to or
refrain from participation in future research at the time of
the initial consent process. They may declare future-use
agreement to join the original study only or any study,
and applications for future use will be reviewed formally.
Discussion
Ischemic stroke is a complex function of multiple genetic
and environmental risk factors. Family-based genetic
study of ischemic stroke can be used to perform linkage
and linkage disequilibrium mapping in pedigrees, and
compared with the standard case-control design, family-
based design has the advantage of robustness to popula-
tion stratification. Some significant findings of predispo-
sitions such as the gene encoding phosphodiesterase 4D
(PDE4D) [28], may vary between populations and the
replications in different studies will provide more power-
ful evidences [29]. Unfortunately, family-based ischemic
stroke study from Asia, especially China, is currently
underrepresented.
Genetic studies in isolated populations, such as the
deCOAD study in Iceland [9], are theoretically robust, but
they require an integrated health care database not availa-
ble in many countries. Although stroke registries have
been established successfully in Western countries, only a
few hospital-based stroke registries have been established
in some cities of China until recently [30]. Multi-centered
study design, like that of the SWISS study [10] in the
United States, may not be appropriate in China because of
quality control and logistic difficulties at the present stage.
Recently a new pedigree study of stroke in Sweden has
been reported [31], and their stroke pedigrees were ascer-
tained retrospectively from a population-based stroke reg-
istry at the northern Sweden MONICA (MONItoring of
trends and determinants in CArdiovascular disease)
Center. Similarly, the SINO-MONICA project [17] facili-
tated epidemiological studies of cardiovascular disease in
some areas of China. The FISSIC study has been inspired
by these studies, but the design differs in many perspec-
tives.
The Fangshan District is a rural mountainous area with a
history of low immigration; family members tend to stay
congregated, consequently genetic diversity in the north-
ern Han Chinese population is relatively low and pedigree
recruitment is convenient. Epidemiological studies of
chronic diseases in this area have long traditions, for
instance the Asia Pacific Cohort Studies Collaboration
(APCSC) [32], many local health care staff has been
trained and some baseline data are available, and mean-
while the public has a favorable attitude towards genetic
research and community consent is probably possible.
Most concerning, however, is the high prevalence of
stroke and hypertension among adults in Fangshan Dis-
trict. Most inhabitants will be hospitalized for stroke
emergency in the First Hospital of Fangshan District
within 6 hours after onset. This hospital keeps detailed
medical records on incident cases and most prevalent
cases from the communities.Page 6 of 9
(page number not for citation purposes)
BMC Medical Genetics 2007, 8:60 http://www.biomedcentral.com/1471-2350/8/60We propose to initially register approximately 500 pedi-
grees in five years. Preliminary pilot study from two com-
munities in Fangshan District showed that the project is
feasible [33]. In the parallel case-control study, unaffected
spouses will serve as matched controls. The use of spousal
controls is convenient and can help control for adult envi-
ronmental exposure. Spouses can be expected to have
spent a large proportion of adulthoods with the patients,
and they likely have shared similar environmental expo-
sures, e.g., diet or exposure to cigarette smoke. Spouses
will also facilitate pedigree recruitment as surrogates of
the probands.
Unaffected controls, especially young siblings, may have
subclinical disease, which could lead to the bias of mis-
classification. In addition to using the QVSFS [18] for val-
idation, longitudinal follow-up will provide a prospective
element to the study. An annual physical examination
and other phenotype data collection will be scheduled for
up to five years in order to investigate changes in stroke-
related phenotypes. This follow-up design allows extend-
ing the pedigree recruitment to more potentially affected
siblings and even offspring in the future.
For environmental exposures not easy to measure by
questionnaire, serum biochemical indicators will be
tested as intermediate phenotypes. For example, homo-
cysteine is an important risk factor for ischemic stroke
[34]; therefore, we will study serum homocysteine and
regard serum folic acid and vitamin B12 level as surrogate
indexes for the environmental factors (vegetable intakes).
As another marker for early carotid atherosclerosis, the
carotid artery intimal medial wall thickness (IMT) by
ultrasonography will be proposed for later study as an
intermediate phenotype for large vessel ischemic stroke
subtype. Intermediate phenotypes represent specific com-
ponents of the disease process and can be expressed as
continuous variables for quantitative trait analysis, rather
than the presence or absence of disease itself [35].
The complexity of ischemic stroke reflects the contribu-
tion of polygenic effects to disease process and the inter-
actions of these multiple genes with a multitude of
environmental factors. Many common genetic factors
individually play little role in the development of
ischemic stroke [8]. However, specific polygenetic pat-
terns, alone or in combination with other common envi-
ronmental factors, can exert a synergistic effect on the
evolution of a specific ischemic stroke subtype. For
instance, synergistic effects in ischemic stroke between the
ACE D/D and MTHFR 677TT genotypes and alcohol
drinking or smoking have been reported by Szolnoki et al
[36]. New advances in the study design and statistical
analysis of family-based studies have expanded the range
of hypotheses that can be tested, including gene-gene and
gene-environment interactions in ischemic stroke. In the
FISSIC program, linkage and family-based association
analyses are applied simultaneously to maximize use of
family data sets, and gene-environment and gene-gene
interactions will be tested by comprehensive methods as
well. Each of these methods offers advantages in different
situations, e.g. the FBAT method is designed to find loci
with main effects instead of interactions, while the MDR
approach is useful in identifying gene-gene interactions
among minor genes [37]. This combined strategy will
help us discern a true association from a spurious finding.
Some limitations of the FISSIC should be mentioned: the
National Institutes of Health Stroke Scale (NIHSS) is not
used to classify stroke by severity, no genome-wide link-
age screen is undertaken and no cell lines are created, for
lack of technical feasibility at the current stage in develop-
ing countries. Although we recognize the value for
genome-wide linkage screen, we will undertake it at a later
stage or bank DNA samples for future research.
Recently the launch of new NCBI database of Genotype
and Phenotype (dbGaP) addresses the critical need for
sharing of genotype and phenotype information, and
thousands of SNPs have been released through collabora-
tions such as the SNP Consortium [38]. Hence, any poten-
tial collaboration proposals are welcome and will be
evaluated by investigators in the FISSIC program to make
full use of the resources available.
In conclusion, the FISSIC program is a family-based
genetic study of ischemic stroke, focusing on the genetic
and environmental determinants and their interactions
with comprehensive strategies. Collecting DNA samples
from a large cohort of ischemic stroke pedigrees in a Chi-
nese population is really a promising challenge rather
than mission impossible. A long-term prospective follow-
up of the pedigree cohort will offer unique resources for
future genetic research on ischemic stroke. The FISSIC is
expected to be a new opportunity to identify stroke predis-
position genes and facilitate initiatives of stroke study for
international collaborations.
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